Medicine and Dentistry
Venetoclax
100%
Inpatient
100%
B-Cell Chronic Lymphocytic Leukemia
75%
COVID-19
50%
Therapeutic Procedure
25%
Adult
25%
Diseases
12%
Leukemia
12%
Patient Care
12%
Clinical Observation
12%
Rituximab
12%
Mortality
12%
Monotherapy
12%
B Lymphocyte Receptor
12%
Obinutuzumab
12%
Experience
12%
Nursing and Health Professions
Venetoclax
100%
Patient
100%
Chronic Lymphatic Leukemia
75%
Clinical Practice
12%
Diseases
12%
Disease Burden
12%
Clinical Observation
12%
Hospital Admission
12%
Disease Exacerbation
12%
Monotherapy
12%
B Lymphocyte Receptor
12%
Rituximab
12%
Time
12%
Mortality
12%
Obinutuzumab
12%
Pharmacology, Toxicology and Pharmaceutical Science
Venetoclax
100%
Chronic Lymphatic Leukemia
75%
Tolerability
25%
Diseases
12%
Monotherapy
12%
Rituximab
12%
B Lymphocyte Receptor
12%
Bruton Tyrosine Kinase Inhibitor
12%
Obinutuzumab
12%
Mortality
12%
Immunology and Microbiology
Disease Burden
12%
Bruton's Tyrosine Kinase
12%
Rituximab
12%
B-Cell Receptor
12%
Mortality
12%
Time
12%
Experience
12%
Obinutuzumab
12%